JAZZ - Jazz Pharmaceuticals beats by $0.62 beats on revenue February, 26 2019 04:14 PM Jazz Pharmaceuticals plc Jazz Pharmaceuticals (NASDAQ:JAZZ): Q4 Non-GAAP EPS of $3.64 beats by $0.62; GAAP EPS of $2.64 beats by $0.65. Revenue of $476.5M (+9.2% Y/Y) beats by $16.83M. Shares +9.8%. Press Release More news on: Jazz Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,